S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48%
Next Bullish Trade
Sign in
AMGN

Amgen Inc. AMGN

$366.29 -5.29 (-1.42%)
Neutral · +0.77σ
Mkt cap $192.6B
P/E 25.1
Day $361.72 – $378.54
52wk $320.52 – $391.29
Avg vol
Beta
Div yld
Next earnings

Quick read

Plain English

Amgen Inc. is a healthcare company listed in the US.

AMGN last traded at $366.29, down 1.4% on the day; that's in the middle part of its 52-week range ($320.52–$391.29). Right now it's trading close to its recent average, with no strong stretch in either direction.

Earnings reports are the biggest scheduled catalysts to keep an eye on, and day to day, watch whether it holds above or slips below its recent average.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

132-Day Trend Zones

Full chart →
21 EMA +1 ATR +2 ATR −2 ATR
O H L C

Under the hood

On the latest daily bar, momentum sits mid-range (RSI 58), the trend is quiet (ADX 15), and volume is about normal (1.1×). On the business side, revenue is growing 6% year over year and the business keeps about 20 cents of every sales dollar as free cash.

Latest-bar indicator readings behind the grade — display-only, they don't move the letter.

Momentum · RSI
58
0–100 · <30 oversold
Trend strength · ADX
15
>25 = strong trend
Volume vs avg
1.08×
1× = average
Stretch from avg
+0.7 ATR
− below · + above
Zone touches
0
tests of this zone
Suggested hold
3–30
bars (≈ days)
Fundamentals at a glance

Company fundamentals for context — display-only, they don't move the grade.

Revenue growth
+5.8%
year over year
Free-cash-flow margin
20.2%
cash kept per $ of sales
Debt / equity
6.24
lower = less leveraged
P/E ratio
25.1
price ÷ yearly profit

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $169.63 (fair range $170–$292); today's price sits 112% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Intrinsic (DCF)
$169.63
Fair-value range
$169.63 – $292.25
Margin of safety
-112%
Verdict
Overvalued
Accounting quality Weak
  • ✓ Gross margin 71% (pricing power)
  • ✓ Net margin 21%
  • ⚠ Debt exceeds cash
  • ⚠ Quick ratio 0.85 (fragile)
  • ⚠ Debt/equity 9.46 (fragile)
  • ⚠ Negative retained earnings

Price implies ~15% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

AMGN is a $192.6 billion company, priced at 25× last year's earnings.

Mkt cap $192.6B
P/E ttm 25.1
Fwd P/E
Beta
Day range $361.72 – $378.54
52w range $320.52 – $391.29
Avg vol
RSI(2) 54.4
ROE
Net mgn
FCF mgn 20.2%
Debt/Eq 6.24
Div yld
Sector Healthcare
Industry Drug Manufacturers - General
Next earn
52-week range · today's price
$320.52$391.29

More on AMGN